MM+M Highlights What’s Next for Pharma—And Where ixlayer Fits
In a recent piece for MM+M, the publication’s “Healthcare Huddle” series examines the ongoing transformation of the pharmaceutical industry. The headline may suggest extinction, but the article emphasizes that pharma is far from dead, though significant threats and opportunities remain.
This discussion identifies precisely the model ixlayer is building: direct-to-patient (DTP) experiences that leverage digital, data and patient centricity to maintain relevance and drive growth.
Key points:
- The industry is operating in a climate of pressure: new entrants, shifting consumer expectations, digital disruption, and value-based care models all combine to raise the stakes for pharma brands.
- According to the article, the brands that succeed will be those that re-engineer the front door to care, making access simpler, more transparent and patient centered.
- ixlayer is cited as part of that structural shift: platforms that allow pharma to move beyond mass marketing and into connected, measurable patient journeys.
“When implemented right, direct-to-patient solutions feel simple and seamless for the patient … and make pharma marketing initiatives more actionable,” says ixlayer’s Matthew Walsh.
The article underscores that while pharma is not dying, the old model, one built on awareness and prescription alone, won’t suffice. Instead, marketing, access, commercial and medical teams must align around journeys, experience and outcomes.
It notes that innovation in patient experience and digital engagement is now a critical strategic lever, not just a nice-to-have. ixlayer’s platform model fits squarely in that terrain: building infrastructure for data-driven, patient-centric solutions.
“What’s striking is that, even with all pharma does to support patients, nearly 80% want more: more access, more ease — more digital-first solutions to help them get the care and medicines they need. In 2025 and beyond, patients won’t just appreciate direct-to-patient health solutions from pharma — they’ll expect them.” Pouria Sanae, CEO and co-founder, ixlayer.
Why this matters for pharma brands and marketing leaders:
- As MM+M emphasizes, the threats to pharma’s relevance aren’t about demise but about missed transformation. Brands failing to modernize risk losing access, trust and patient choice.
- Platforms like ixlayer illustrate how the model can shift: from “awareness → prescription” to “awareness → action → outcome.”
- For marketing teams, the metric of success moves: it’s not just reach or share of voice, but time to care, patient engagement, adherence and data-driven loops.
A strategic takeaway: if pharma wants to remain central in healthcare ecosystems, it must become part of the care delivery front door, and building that door means partner platforms, digital models and patient-centric design.
Read ixlayer’s EOY research report: Closing the Awareness Gap: What Pharma Executives and Patients Expect from Direct-to-Patient Programs in 2025
Read MM+M’s coverage of ixlayer: https://www.mmm-online.com/features/healthcare-huddle-reports-of-pharmas-death-greatly-exaggerated-threats-linger/
About ixlayer
ixlayer has the only end-to-end, direct-to-patient platform built for biopharma and optimized for patient choice. We help biopharma companies connect with patients from testing to treatment with speed, transparency, control and impact.
